Innovent Biologics Statistics

Total Valuation

IVBXF has a market cap or net worth of 15.40 billion. The enterprise value is 14.71 billion.

Market Cap	15.40B
Enterprise Value	14.71B

Important Dates

The next estimated earnings date is Wednesday, June 11, 2025.

Earnings Date	Jun 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	1.65B
Shares Outstanding	n/a
Shares Change (YoY)	+4.35%
Shares Change (QoQ)	+0.57%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.53B

Valuation Ratios

PE Ratio	n/a
Forward PE	274.27
PS Ratio	11.93
PB Ratio	8.57
P/TBV Ratio	8.77
P/FCF Ratio	349.70
P/OCF Ratio	87.32
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1,134.70
EV / Sales	11.51
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	334.14

Financial Position

The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.22.

Current Ratio	2.35
Quick Ratio	2.08
Debt / Equity	0.22
Debt / EBITDA	50.93
Debt / FCF	8.81
Interest Coverage	-4.09

Financial Efficiency

Return on equity (ROE) is -0.74% and return on invested capital (ROIC) is -1.08%.

Return on Equity (ROE)	-0.74%
Return on Assets (ROA)	-0.82%
Return on Invested Capital (ROIC)	-1.08%
Return on Capital Employed (ROCE)	-1.60%
Revenue Per Employee	228,102
Profits Per Employee	-2,291
Employee Count	5,659
Asset Turnover	0.45
Inventory Turnover	2.69

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +114.93% in the last 52 weeks. The beta is 0.23, so IVBXF's price volatility has been lower than the market average.

Beta (5Y)	0.23
52-Week Price Change	+114.93%
50-Day Moving Average	6.54
200-Day Moving Average	5.42
Relative Strength Index (RSI)	80.12
Average Volume (20 Days)	8,699

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, IVBXF had revenue of 1.29 billion and -12.96 million in losses. Loss per share was -0.01.

Revenue	1.29B
Gross Profit	960.41M
Operating Income	-37.89M
Pretax Income	-10.77M
Net Income	-12.96M
EBITDA	3.29M
EBIT	-37.89M
Loss Per Share	-0.01

Full Income Statement

Balance Sheet

The company has 1.08 billion in cash and 387.86 million in debt, giving a net cash position of 692.24 million.

Cash & Cash Equivalents	1.08B
Total Debt	387.86M
Net Cash	692.24M
Net Cash Per Share	n/a
Equity (Book Value)	1.80B
Book Value Per Share	1.10
Working Capital	808.86M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 176.33 million and capital expenditures -132.30 million, giving a free cash flow of 44.03 million.

Operating Cash Flow	176.33M
Capital Expenditures	-132.30M
Free Cash Flow	44.03M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 74.40%, with operating and profit margins of -2.94% and -1.00%.

Gross Margin	74.40%
Operating Margin	-2.94%
Pretax Margin	-0.83%
Profit Margin	-1.00%
EBITDA Margin	0.25%
EBIT Margin	-2.94%
FCF Margin	3.41%

Dividends & Yields

IVBXF does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.35%
Shareholder Yield	n/a
Earnings Yield	-0.08%
FCF Yield	0.29%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

IVBXF has an Altman Z-Score of 3.86.

Altman Z-Score	3.86
Piotroski F-Score	n/a